MLYS4:30 PMMineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026Presentation / Abstract • Phase 3presentation Fri, Oct 2, 2026, 4:30 PM EDTGmineralystx.com
MLYS4:05 PMMineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026Presentation / Abstract • Phase 2Oral presentation Thu, Oct 8, 2026, 11:45 AM ETGmineralystx.com
MLYS4:05 PMMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)mineralystx.com
MLYS4:05 PMMineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forummineralystx.com
MLYS4:05 PMMineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026Presentation / AbstractAHA Scientific Sessions late-breaking presentation Sun, Nov 8, 2026, 3:30 PM CTGmineralystx.com
MLYS4:05 PMMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)mineralystx.com
MLYS4:05 PMMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)mineralystx.com
MLYS8:00 AMMineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conferencemineralystx.com
MLYS4:05 PMMineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)mineralystx.com
MLYS4:05 PMMineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updatemineralystx.com
MLYS8:00 AMMineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026mineralystx.com
MLYS4:01 PMMineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)mineralystx.com